Curium has reintroduced thallium-201 (Tl-201) radiotracer in the U.S., restoring access to a radiopharmaceutical used in nuclear cardiology imaging prior to production ceasing in 2022.
Tl-201 is used for myocardial perfusion imaging with planar scintigraphy or SPECT to diagnose coronary artery disease, including viability testing in settings where PET or MRI may be unavailable or impractical, Curium said.
The radiopharmaceutical will be produced at the company’s facility in Maryland Heights, MO, supported by investments including cyclotron upgrades, processing and filing infrastructure, staffing and training, and expanded quality-control resources, Curium noted.
